Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

NCT06747845 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma Metastatic

Interventions

DRUG: Niraparib
DRUG: FOLFIRI
DRUG: Ipilimumab

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

[object Object]
[object Object]
[object Object]